Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: comparison of clinical results obtained with BNCT and conventional treatment.

Abstract

The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma. Since 1998 we treated 23 newly-diagosed GBM patients with BNCT without any additional chemotherapy. Their median survival time was 19.5 months; the 2-, 3-, and 5-year survival rates were 31.8%, 22.7%, and 9.1%, respectively. The clinical results of BNCT in patients with GBM are similar to those of recent conventional treatments based on radiotherapy with concomitant and adjuvant temozolomide.

• Authors: Teruyoshi Kageji, Shinji Nagahiro, Yoshifumi Mizobuchi, Kazuhito Matsuzaki, Yoshinobu Nakagawa, Hiroaki Kumada
• Journal: The journal of medical investigation : JMI (J Med Invest) Vol. 61 Issue 3-4 Pg. 254-63 ( 2014) ISSN: 1349-6867 [Electronic] Japan
• PMID: 25264042 (Publication Type: Comparative Study, Journal Article, Review)

Topics

• Adolescent
• Adult
• Aged
• Boron Neutron Capture Therapy
• Brain Neoplasms (mortality, radiotherapy)
• Child
• Glioblastoma (mortality, radiotherapy)
• Humans
• Middle Aged
• Survival Rate